Aligos Therapeutics Inc ALGS
$6.67 $0.23 (3.57%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
ALGS Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Aligos Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Aligos Therapeutics Inc. Stock Analysis ALGS
United States Health Care Nano Cap Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 82 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Aligos Therapeutics Inc (ALGS) Chart
Financial Metrics & Statements of Aligos Therapeutics Inc (ALGS)
FAQ's for Aligos Therapeutics Inc (ALGS)
- As of August 2026, Aligos Therapeutics Inc ALGS is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Aligos Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Aligos Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Aligos Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Aligos Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Aligos Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Aligos Therapeutics Inc (ALGS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
